+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Fibrosis Drugs Market - Global Forecast 2026-2032- Product Image
Liver Fibrosis Drugs Market - Global Forecast 2026-2032- Product Image
New

Liver Fibrosis Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904956
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver fibrosis drugs market is experiencing a period of accelerated evolution, compelling senior decision-makers to align organizational strategies with emerging innovations and regulatory shifts. Success depends on anticipatory adaptation and informed, agile leadership amidst increasingly complex industry dynamics.

Market Snapshot: Liver Fibrosis Drugs Market Outlook

The liver fibrosis drugs market is forecast to expand significantly, rising from USD 17.12 billion in 2025 to USD 18.83 billion in 2026 and reaching USD 33.70 billion by 2032, reflecting a CAGR of 10.15%. Growth is fueled by robust R&D investment, a responsive policy landscape, and rising adoption of performance-based reimbursement models. Organizations must navigate evolving compliance demands and competitive intensity, targeting value creation through innovation and strategic alignment with payer and regulatory expectations. The shifting market landscape necessitates continual review of operational priorities, technology partnerships, and go-to-market plans to ensure leadership continuity.

Liver Fibrosis Drugs Market Scope & Segmentation

  • Therapeutic Classes: Biologics, cell therapies, gene therapies, and small molecule inhibitors, with biologics further segmented into monoclonal antibodies and recombinant proteins. Each class offers unique therapeutic and economic value, enabling tailored approaches throughout disease management.
  • Mechanism of Action: Drugs target critical disease pathways including stress kinases, galectin activity, and nuclear receptors. Strategies also include modulating TGF-beta signaling, reflecting an emphasis on multi-target mechanisms for complex disease profiles.
  • Route of Administration: Available as injectable (intravenous and subcutaneous) and oral formulations. The chosen route influences care models, clinical processes, and patient adherence programs.
  • Distribution Channels: Pathways include hospital pharmacies, online outlets, retail chains, and independent pharmacies, each with distinct requirements for supply partnerships and local market integration.
  • Geographic Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific—all with unique regulatory, payer, and market access considerations, demanding precise, region-specific commercialization and trial strategies.
  • Technology Drivers: Includes biomarker-enabled patient selection, companion diagnostics, and digital adherence platforms. Integrating these technologies supports precision medicine, enhances outcome tracking, and underpins arguments for broader reimbursement access.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Therapeutic R&D strategies are increasingly focused on patient and disease variability, with a trend towards precision modalities addressing both metabolic and fibrogenic drivers.
  • Combinatorial therapeutics unite small molecules with next-generation biologics or cell-based treatments to activate multiple mechanisms, providing opportunities for synergistic benefits.
  • Regulatory authorities and payers seek greater validation through strategic biomarker use, refined clinical trial design, and early dialog, impacting reimbursement and market entry.
  • Commercialization approaches now extend beyond conventional pharmacotherapies, integrating diagnostics and digital tools to align real-world evidence with payer and provider goals.
  • Strategic collaborations across pharma, biotech, contract research, and diagnostics foster operational scalability and boost go-to-market effectiveness through resource and process integration.

Tariff Impact: Navigating Policy Shifts in 2025

New U.S. tariffs set to take effect in 2025 are expected to introduce uncertainty around supply chain costs and pricing for liver fibrosis therapies. Anticipating shifts in manufacturing strategy, companies may increase local production and operational efficiency investments. Adjusting procurement models and establishing robust multi-sourcing agreements can bolster supply resilience and secure continuity. The market is likely to see an emphasis on value-based contracts, supported by credible health-economic outcomes. Engaging policymakers early and preparing for varied policy scenarios will be vital to maintaining patient access and mitigating risk.

Methodology & Data Sources

This research utilizes a mixed-methods design, combining review of recent literature, regulatory files, and clinical trial databases with expert interviews. Data validity is ensured through secondary analysis of industry partnership reports and key supply chain indicators, with transparent reporting of sources and cut-off dates to guarantee reliability.

Why This Report Matters

  • Provides robust benchmarking for commercialization and development initiatives in the liver fibrosis drugs sector, leveraging up-to-date clinical and regulatory trends.
  • Offers actionable segmentation and market insights to optimize investments and partnerships across diverse regulatory and access environments.
  • Guides supply chain scenario planning and payer strategy formulation to minimize market entry risks and support resilient market participation.

Conclusion

Achieving and sustaining market leadership in the liver fibrosis drugs sector requires a coordinated approach to scientific advancement, supply strategy, and strategic stakeholder engagement. These insights support confident, future-facing decision-making in a dynamic environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Liver Fibrosis Drugs Market, by Drug Class
8.1. Biologic Therapies
8.1.1. Monoclonal Antibodies
8.1.2. Recombinant Proteins
8.2. Cell Therapies
8.3. Gene Therapies
8.4. Small Molecule Inhibitors
8.4.1. Natural Products
8.4.2. Synthetic Compounds
9. Liver Fibrosis Drugs Market, by Mechanism Of Action
9.1. ASK1 Inhibitors
9.2. Galectin-3 Inhibitors
9.3. PPAR Agonists
9.3.1. PPAR Alpha
9.3.2. PPAR Delta
9.3.3. PPAR Gamma
9.4. TGF Beta Blockers
10. Liver Fibrosis Drugs Market, by Route Of Administration
10.1. Injectable
10.1.1. Intravenous
10.1.2. Subcutaneous
10.2. Oral
11. Liver Fibrosis Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
12. Liver Fibrosis Drugs Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Liver Fibrosis Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Liver Fibrosis Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Liver Fibrosis Drugs Market
16. China Liver Fibrosis Drugs Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Akero Therapeutics, Inc.
17.6. AstraZeneca plc
17.7. BioLineRx Ltd.
17.8. Boehringer Ingelheim International GmbH
17.9. Bristol-Myers Squibb Company
17.10. FibroGen, Inc.
17.11. Galectin Therapeutics, Inc.
17.12. Galmed Pharmaceuticals Ltd.
17.13. Gilead Sciences, Inc.
17.14. Hepion Pharmaceuticals, Inc.
17.15. Intercept Pharmaceuticals, Inc.
17.16. Inventiva S.A.
17.17. Ionis Pharmaceuticals, Inc.
17.18. Johnson & Johnson Services, Inc.
17.19. Madrigal Pharmaceuticals, Inc.
17.20. Merck & Co., Inc.
17.21. Novartis AG
17.22. Novo Nordisk A/S
17.23. Pfizer Inc.
17.24. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 124. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 127. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 132. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 147. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 152. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 168. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 170. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 175. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 177. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 178. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 179. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 180. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 181. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 183. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 195. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 198. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 200. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 201. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 203. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 205. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 208. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 210. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 211. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 213. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 215. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 218. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 220. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 221. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 223. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 236. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 239. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 240. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 241. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
TABLE 242. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 244. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Liver Fibrosis Drugs market report include:
  • Akero Therapeutics, Inc.
  • AstraZeneca plc
  • BioLineRx Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Hepion Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva S.A.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 18.83 Billion
Forecasted Market Value ( USD ) by 2032 $ 33.7 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Liver Fibrosis Drug Pipeline Analysis Report 2025 - Product Image

Liver Fibrosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Liver Fibrosis Market Report and Forecast 2025-2034 - Product Image

Liver Fibrosis Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Liver Fibrosis- Pipeline Insight, 2025 - Product Image

Liver Fibrosis- Pipeline Insight, 2025

  • Drug Pipelines
  • 85 Pages
  • Global
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025 - Product Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From

About the Liver Fibrosis Drug Market

The Liver Fibrosis Drug market is a subset of the pharmaceutical industry focused on the development of treatments for liver fibrosis. Clinical trials are a key component of the development process, as they provide evidence of the safety and efficacy of a drug. Clinical trials are conducted in phases, with each phase providing increasingly detailed information about the drug's effects. The first phase of a clinical trial typically involves a small number of participants and is designed to assess the safety of the drug. Subsequent phases involve larger numbers of participants and are designed to assess the efficacy of the drug. The Liver Fibrosis Drug market is highly competitive, with many companies vying for a share of the market. Companies in the market include Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.